What Actually Changed With Humira in 2026
Humira held the title of best-selling drug in the world for over a decade, generating more than $20 billion annually at its peak. That changed once AbbVie's patent wall came down and the first biosimilar, Amjevita, launched in January 2023. Nine more followed across 2023 through 2026, and by mid-2026 biosimilars account for the large majority of new adalimumab prescriptions filled in the U.S.
The headline development this year isn't a new biosimilar launch — it's AbbVie's decision to close its own patient assistance program to new Humira applicants on July 1, 2026. That single change reshapes the financial-assistance landscape for anyone starting adalimumab therapy without insurance, and it's the first thing this guide addresses in the sections below on copay cards and patient assistance.
At the same time, insurance formularies have quietly shifted. Most commercial plans and a growing share of Medicare Part D plans now list one or more biosimilars as preferred, while Humira itself sits in a non-preferred tier with a higher copay or coinsurance. For many patients, the biggest cost lever in 2026 isn't which pharmacy they use — it's which specific adalimumab product their plan prefers.
Complete List of Humira Biosimilars (2026)
Ten adalimumab biosimilars are FDA-approved as of mid-2026. They differ by concentration (low vs. high), citrate content, device type, and interchangeable status — details that matter more for day-to-day use than most patients expect.
| Biosimilar | Manufacturer | Interchangeable? | Concentration |
|---|---|---|---|
| Amjevita (adalimumab-atto) | Amgen | Yes | Low & high |
| Cyltezo (adalimumab-adbm) | Boehringer Ingelheim | Yes | Low & high |
| Hyrimoz (adalimumab-adaz) | Sandoz | Yes | Low & high |
| Hulio (adalimumab-fkjp) | Biocon / Viatris | Yes | Low & high |
| Simlandi (adalimumab-ryvk) | Alvotech / Teva | Yes | High (citrate-free) |
| Yuflyma (adalimumab-aaty) | Celltrion | Yes | High |
| Abrilada (adalimumab-afzb) | Pfizer | Yes | Low & high |
| Hadlima (adalimumab-bwwd) | Samsung Bioepis / Organon | Case-by-case by state | Low & high |
| Idacio (adalimumab-aacf) | Fresenius Kabi | No | High |
| Yusimry (adalimumab-aqvh) | Coherus BioSciences | No | High |
Interchangeable status can be updated by the FDA at any time and is tracked in the agency's Purple Book. Confirm current status before assuming a pharmacy-level swap is allowed — a handful of states also restrict or add notification requirements for interchangeable substitution regardless of federal designation.
Cost Comparison: Humira vs. Biosimilars
List price is a starting point, not what most patients actually pay. Your real cost depends on insurance tier placement, deductible status, copay card eligibility, and pharmacy channel. Still, the spread between Humira and its biosimilars is large enough to matter even after insurance.
| Product | Approx. Cash Price / Month | With Manufacturer Copay Card | Typical Commercial Insurance Copay |
|---|---|---|---|
| Humira (brand) | ~$6,900 | $0–$5 (if eligible) | $25–$100 (preferred) / $100+ (non-preferred) |
| Unbranded adalimumab-adbm (Cyltezo unbranded) | ~$550–$600 | $0–$25 (if offered) | $0–$50 |
| Hyrimoz / Cyltezo (branded) | ~$1,000–$1,500 | $0–$25 | $0–$50 |
| Amjevita / Hadlima / Hulio | ~$1,200–$2,000 | $0–$25 | $0–$75 |
| Yusimry (cash-pay focused) | ~$570–$650 | Limited program | Varies by plan |
The gap that matters most: for uninsured patients, choosing an unbranded high-discount biosimilar over brand Humira is roughly a 90% cost reduction before any assistance program is applied. For insured patients, the bigger lever is usually formulary tier, since a preferred biosimilar can carry a $0 copay while Humira on the same plan carries a much higher one.
Copay Cards & Manufacturer Savings Programs
Every major adalimumab manufacturer runs a copay assistance program for commercially insured patients. None of these programs can be used by patients on government insurance, and all have an annual maximum benefit that can run out before the plan year ends if you're also subject to a copay accumulator or maximizer program on your plan.
| Product | Copay Program | Typical Out-of-Pocket | Government Insurance Eligible? |
|---|---|---|---|
| Humira | Humira Complete Savings Card | As low as $5/month | No |
| Amjevita | Amgen Assist 360 | Reduced copay, commercial only | No |
| Hyrimoz | Sandoz One Source | Copay card + patient support | No |
| Cyltezo | Boehringer Ingelheim savings program | Reduced copay, commercial only | No |
| Hadlima | Samsung Bioepis / Organon patient support | Reduced copay, commercial only | No |
If you're subject to a copay accumulator or maximizer, the dollar amount your copay card covers doesn't count toward your deductible or out-of-pocket maximum — so the card can run out mid-year even though your deductible looks untouched on paper. This is one of the most common reasons a Humira or biosimilar copay suddenly jumps in the fall. See our guide to copay accumulator and maximizer programs for how to check whether your plan does this and what to do about it.
The AbbVie PAP Closure: What It Means for Uninsured Patients
AbbVie's myAbbVie Assist program — the traditional safety net for uninsured or underinsured Humira patients — stopped accepting new Humira applications as of July 1, 2026. Patients already enrolled before that date are generally grandfathered through their current enrollment period, but new applicants are being directed toward biosimilar alternatives instead.
If you're uninsured and were planning to apply for free Humira through AbbVie: that door is now closed for new applicants. Your realistic paths are a biosimilar manufacturer's own patient assistance program, an independent charitable foundation grant, or a cash-pay unbranded biosimilar through a discount program.
Independent, disease-specific foundations — including organizations like the PAN Foundation and the HealthWell Foundation — continue to offer copay and premium assistance grants for eligible patients regardless of which adalimumab product they're prescribed, and these grants are typically open to Medicare beneficiaries as well, unlike manufacturer copay cards. Our general PAP application walkthrough covers what documentation these foundations typically require.
Interchangeable vs. Non-Interchangeable: Why It Matters
"Biosimilar" and "interchangeable" are not the same thing, and the difference decides whether you need a new prescription to switch.
- Biosimilar: FDA has confirmed the product is highly similar to Humira with no clinically meaningful differences in safety or effectiveness. A new prescription is required to start it.
- Interchangeable: FDA has gone a step further and confirmed the product can be substituted for Humira at the pharmacy counter without contacting the prescriber, similar to how a generic pill is substituted for a brand-name tablet — subject to your state's specific pharmacy substitution law.
| Status | Pharmacist Can Substitute? | New Prescription Needed? |
|---|---|---|
| Interchangeable (e.g., Cyltezo, Hyrimoz, Amjevita) | Usually yes, per state law | Usually no |
| Biosimilar, not interchangeable (e.g., Idacio, Yusimry) | No | Yes |
Clinically, there's no meaningful safety difference between interchangeable and non-interchangeable adalimumab biosimilars — the designation is a regulatory and pharmacy-substitution distinction, not a quality tier. Non-interchangeable products have simply not gone through (or completed) the additional switching studies the FDA requires for that specific label.
How to Switch From Humira to a Biosimilar
The mechanics differ slightly depending on whether your insurer initiated the switch (common with formulary changes) or you're asking your prescriber to switch you to save money. Either way, the sequence below avoids the two most common failure points: a gap in your injection supply, and a denied claim because the new product wasn't pre-authorized.
Check your plan's current formulary for adalimumab
Call your insurer or check your plan's online formulary tool to see which adalimumab products are preferred this year. Formularies change annually, sometimes mid-year, and the preferred product on your plan may not be the cheapest one at cash price.
Confirm interchangeable status and your state's substitution rule
If the biosimilar you want is interchangeable, your pharmacist may be able to make the switch directly. If it isn't, you'll need a new prescription regardless of what your insurer prefers.
Talk to your prescriber before the switch, not after
Even for interchangeable products, tell your prescriber you're switching. They'll want to confirm the new product covers your specific diagnosis and that the device (pen vs. syringe) matches what you can safely self-inject.
Get a new prior authorization if your plan requires one
Many plans require a fresh prior authorization for adalimumab products even when only the manufacturer changes. Ask your prescriber's office to submit this before your current supply runs out, not after.
Enroll in the new product's copay card, if eligible
Copay cards don't transfer automatically between manufacturers. Enroll in the biosimilar's specific savings program before your first fill so the discount applies at the counter instead of requiring a rebate claim later.
Request injection training for the new device
Pen mechanisms, needle gauge, and injection sites can differ slightly between manufacturers. Most specialty pharmacies include a quick training call or video with the first shipment of a new product — take it, even if you're an experienced Humira user.
Decision Tree: Which Path Fits Your Situation?
Start Here
Do you currently have commercial insurance (not Medicare/Medicaid/TRICARE)?
Check formulary tier
Is a biosimilar preferred over Humira on your plan?
Switch to the preferred biosimilar
Confirm interchangeable status, then enroll in that product's copay card.
Check income eligibility
Do you qualify for a biosimilar manufacturer's PAP or a charitable foundation grant?
Apply for assistance, or use cash-pay biosimilar
If ineligible for assistance, price an unbranded biosimilar through a discount program.
Real-World Examples
Commercially insured patient, plan just changed its formulary
A patient on Humira for Crohn's disease receives a letter that their plan is moving Humira to non-preferred status starting next quarter, with Cyltezo listed as preferred. Because Cyltezo carries the interchangeable designation, the patient's specialty pharmacy coordinates the switch directly with the prescriber, submits a new prior authorization proactively, and the patient enrolls in Boehringer Ingelheim's savings program before the first fill — avoiding any lapse in treatment or a surprise bill.
Uninsured patient who lost employer coverage in June 2026
A patient with psoriatic arthritis loses job-based insurance and can no longer afford Humira's list price. Because AbbVie's PAP closed to new applicants on July 1, 2026, they instead price an unbranded adalimumab biosimilar through a discount program at roughly $580 per carton, then separately apply to an independent charitable foundation for additional copay-style grant support while between jobs.
Medicare Part D beneficiary comparing adalimumab products
A Medicare patient on a Part D plan finds that their plan's 2026 formulary places two specific biosimilars in a lower cost-sharing tier than Humira. Since manufacturer copay cards aren't available to them, they apply to the HealthWell Foundation's adalimumab-related grant program instead, which — unlike manufacturer cards — accepts Medicare beneficiaries who meet income requirements.
Medicare and Adalimumab Coverage
Adalimumab products are almost always billed through Medicare Part D as a self-administered specialty drug, not Part B, since Part B generally covers only drugs administered in a clinical setting by a provider. A physician-administered adalimumab claim would use HCPCS code J0139, but this applies to a small minority of cases where a patient can't self-inject and receives the drug in an office or infusion setting.
- Part D formularies vary by plan and increasingly prefer specific biosimilars over brand Humira.
- Manufacturer copay cards cannot be used by Medicare beneficiaries under federal anti-kickback rules.
- Independent charitable foundations remain the primary copay-assistance path for Medicare patients on adalimumab.
- If your plan doesn't cover the specific product your prescriber wants, a formulary exception request — supported by your prescriber — is the standard next step. See our formulary exception walkthrough for how that request is typically structured.
Common Mistakes When Switching
- ☐ Switching products without confirming a new prior authorization is filed first.
- ☐ Assuming a copay card transfers automatically between manufacturers — it doesn't.
- ☐ Not checking whether the new biosimilar's approved indications match your specific diagnosis.
- ☐ Skipping injection device training when switching between pen and syringe formats.
- ☐ Waiting until your current supply runs out before starting the switch paperwork.
- ☐ Assuming Medicare patients can use manufacturer copay cards — they cannot.
- ☐ Not confirming whether your plan applies a copay accumulator, which can silently drain your card's annual maximum.
The single most common delay reported by specialty pharmacies is a switch initiated at the pharmacy level before the new prior authorization was approved, resulting in a rejected claim at pickup. Start authorization paperwork the same week you decide to switch, not the day your refill is due.
Bottom Line
The Humira biosimilar market matured fast: ten FDA-approved products, most of them interchangeable, and price points running as low as 8–10% of Humira's list price for cash-pay patients. The 2026 wrinkle is AbbVie stepping back from its own patient assistance program, which pushes uninsured patients toward biosimilar-specific assistance and independent charitable foundations instead.
For most commercially insured patients, the fastest way to lower cost is checking your plan's current formulary preference and enrolling in that specific product's copay card before your next fill. For anyone without commercial insurance, an unbranded biosimilar through a discount program, paired with a charitable foundation grant if eligible, now does the job the AbbVie PAP used to do.
Not sure which adalimumab product fits your coverage?
Talk to your prescriber's office about your plan's current formulary before your next refill, and ask your pharmacist whether an interchangeable substitution is available where you live.
See the Decision Tree → Compare Copay CardsFrequently Asked Questions
Unbranded adalimumab-adbm, distributed through discount programs like GoodRx, is typically the lowest-priced option at roughly $550 to $600 per carton without insurance — an estimated 90% or more below Humira's list price. Branded biosimilars such as Hyrimoz, Cyltezo, and Yusimry also carry list prices deeply discounted from Humira, though your actual out-of-pocket cost depends on your specific insurance plan and pharmacy.
Only if the biosimilar carries the FDA's interchangeable designation and your state's pharmacy substitution laws permit it. Interchangeable products — currently including Amjevita, Cyltezo, Hyrimoz, Hulio, Simlandi, Yuflyma, and Abrilada — can generally be substituted the same way a generic pill replaces a brand-name tablet. Non-interchangeable biosimilars require a new prescription written specifically for that product.
Clinical trials required for FDA approval show no meaningful difference in safety, effectiveness, or immune response between Humira and its approved biosimilars. Large-scale switching studies conducted internationally, where biosimilar adoption happened years earlier, have not found increased disease flares or safety signals tied to the switch itself.
It depends on your plan's formulary tier placement and whether the biosimilar's manufacturer offers a copay card. Many commercial plans have moved preferred formulary status to specific biosimilars, which can lower your copay, while Humira may move to a non-preferred tier with a higher out-of-pocket cost.
Most biosimilar manufacturers, including Amgen, Sandoz, Boehringer Ingelheim, and Samsung Bioepis/Organon, run comparable copay assistance programs for commercially insured patients, often reducing monthly costs to a low fixed amount. Terms, annual maximums, and eligibility rules vary by manufacturer, so it's worth comparing the specific program tied to the biosimilar you're considering.
No. Federal anti-kickback rules prohibit manufacturer copay cards for patients enrolled in Medicare, Medicaid, TRICARE, or other government insurance, and this applies equally to Humira and its biosimilars. Medicare patients should instead look at their plan's specific formulary placement for adalimumab products, independent charitable copay foundations, and manufacturer patient assistance programs for uninsured or low-income beneficiaries.
Multiple switches among adalimumab products, sometimes called a switching cascade, have not shown increased safety risk in published studies, but frequent switching can complicate dose tracking and injection device training since pens and syringes differ by manufacturer. Confirm with your prescriber and pharmacist each time your product changes so your records and injection technique stay current.
Many commercial plans and Medicare Part D formularies have shifted to preferring one or more biosimilars over brand-name Humira, sometimes requiring a formulary exception request if a prescriber wants to keep a patient on Humira specifically. This is a step therapy or formulary management decision made by the plan, not a safety requirement.
AbbVie closed its myAbbVie Assist patient assistance program to new Humira applicants as of July 1, 2026, in step with declining brand-name utilization as biosimilars take over most of the adalimumab market. Patients who need free or low-cost adalimumab going forward should look at patient assistance programs offered by individual biosimilar manufacturers or independent charitable foundations.
As of mid-2026, the FDA has approved ten adalimumab biosimilars referencing Humira, and at least seven carry the interchangeable designation. New approvals and interchangeability designations continue to be added, so the exact count can shift year to year.
Most Humira biosimilars are approved for the same core indications, including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, plaque psoriasis, Crohn's disease, and ulcerative colitis, though a small number carry a narrower label. Confirm your specific diagnosis is covered on the biosimilar's label before switching.
How We Researched This Guide
References
- U.S. Food & Drug Administration. Purple Book Database of Licensed Biological Products (Interchangeability Records).
- Centers for Medicare & Medicaid Services. Medicare Part D Prescription Drug Coverage Guidance.
- GoodRx. Humira Biosimilars: Approved Options and Pricing.
- Association for Accessible Medicines. Biosimilars Market Research and Access Reports.
Related Resources
Related Prescription Savings Guides
- Copay Accumulator and Maximizer Programs Explained
- How to File a Formulary Exception Appeal
- Patient Assistance Program Application Guide
- What Is a Specialty Pharmacy and Why It Matters for Biologics
- Medicare Part D vs. Part B: Which Covers Your Prescription
- 2026 Drug Shortage Tracker
- Biosimilar vs. Generic Drugs: What's the Difference
Editorial Policy: Refill Relay content is researched using FDA records, manufacturer program materials, and standard industry application practices. Every article is reviewed for clarity, accuracy and usefulness before publication.